Back to Agenda
International Regulatory Advertising and Promotion Considerations
Session Chair(s)
Thomas M. Casola, MBA
Head, Global Regulatory Affairs, Advertising and Promotion
Shire Specialty Pharmaceuticals, United States
Requirements for disclosure of payments to health care professionals are changing the nature of relationships between pharmaceutical manufacturers and health care practitioners. The impact of the Sunshine Act is already being seen in the US market and new transparency requirements are now being rolled out in International markets. This session will review transparency requirements, what companies should be thinking about to prepare for new disclosure rules in International markets, and how these requirements will affect both commercial and drug development activities.
Learning Objective : Discuss how to remain compliant in the international marketing arena.
Speaker(s)
Industry Perspective
Laurent Clerc
BMI System Inc., France
Regulatory Affairs Specialist
Industry Perspective
Jonathon L. Kellerman
PricewaterhouseCoopers LLP, United States
Partner, Pharmaceutical and Life Sciences Advisory
Industry Perspective
Ross Weaver
Amgen, Inc., United States
Executive Director, Global Healthcare Compliance Operations
Industry Perspective
Anthony Brennan
Janssen Pharmaceutical Research & Development, LLC, United States
Senior Director, Compliance, HCC
Have an account?